
Please try another search
For the fiscal year ended 30 June 2021, Alterity Therapeutics Ltd (ADR) revenues increased 21% to A$21K. Net loss increased 14% to A$15.3M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Higher net loss reflects Other research and development expenses increase of 37% to A$10.1M (expense), Employee expenses (non R&D related) increase from A$618K to A$1.6M (expense).
Period Ending: | Jun 30, 2021 | Dec 31, 2020 | Jun 30, 2020 | Dec 31, 2019 |
---|---|---|---|---|
Total Revenue | 0.01 | 0.01 | 0 | 0.01 |
Gross Profit | ||||
Operating Income | -7.52 | -7.71 | -8.02 | -5.77 |
Net Income | -6.75 | -8.56 | -7.82 | -5.64 |
Period Ending: | Jun 30, 2021 | Dec 31, 2020 | Jun 30, 2020 | Dec 31, 2019 |
---|---|---|---|---|
Total Assets | 33.59 | 37.41 | 9.91 | 14.49 |
Total Liabilities | 3.12 | 3.05 | 2.76 | 3.29 |
Total Equity | 30.47 | 34.36 | 7.15 | 11.2 |
Period Ending: | Jun 30, 2021 | Dec 31, 2020 | Jun 30, 2020 | Dec 31, 2019 |
---|---|---|---|---|
Period Length: | 12 Months | 6 Months | 12 Months | 6 Months |
Cash From Operating Activities | -17.33 | -7.33 | -9.43 | -2.59 |
Cash From Investing Activities | -0.01 | -0 | -0.02 | -0.01 |
Cash From Financing Activities | 36.69 | 34.17 | 3.98 | 0.24 |
Net Change in Cash | 18.92 | 25.85 | -5.2 | -2.22 |
Unlock access to over 1000 metrics with InvestingPro
View advanced insights on financial statements, including growth rates and metrics that provide an in-depth view of the company's historical and forecasted financial performance.
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review